Skip to content

Pentazocine With Rectal Diclofenac Versus Pentazocine Alone for Pain Relief Following Caesarean Delivery: A Randomised Controlled Trial

Pentazocine With Rectal Diclofenac Versus Pentazocine Alone for Pain Relief Following Caesarean Delivery: A Randomised Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202107706925314
Enrollment
200
Registered
2021-07-28
Start date
2021-07-26
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caesarean Delivery

Interventions

Pentazocine only group
Pentazocine and Rectal Diclofenac Group

Sponsors

Ofor Ifeanyichukwu
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: All consenting women with lower segment caesarean delivery under spinal anaesthesia Women with term gestations (37-42 weeks) Women with singleton pregnancy

Exclusion criteria

Exclusion criteria: Women with known history of peptic ulcer disease Women with allergies to NSAIDs and pentazocine Sickle cell disease patients Asthmatic patients Patients who had still births Patients with opiod dependency Obese women Patients who had still births Patients with morbidities that may affect pain management Patients who may have complicated and prolonged surgeries (lasting over 90 minutes)

Design outcomes

Primary

MeasureTime frame
The level of pain perception measured using the VAS for pain.

Secondary

MeasureTime frame
Level of satisfaction with pain relief, ;Need for breakthrough analgesia;Maternal side effects;Time of onset of bowel movement;Time of onset of ambulation

Countries

Nigeria

Contacts

Public ContactIfeanyichukwu Ofor

Specialist Registrar

ofor.ifeanyi@gmail.com+2348037547411

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026